Edgewise Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $114,357,000.
Profit Margin
| 2019 | 0 | -9.48M | |
|---|---|---|---|
| 2020 | 0 | -17.05M | |
| 2021 | 0 | -42.13M | |
| 2022 | 0 | -15.39M | |
| 2023 | 0 | -100.16M |
EWTX Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 1.73M | 538K | 272K | 185K | 123K |
Gross profit | -1.73M | -538K | -272K | -185K | -123K |
Operating exp. | |||||
Research and development | 90.90M | 16.61M | 32.18M | 14.98M | 8.62M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 114.35M | 22.07M | 43.21M | 17.19M | 9.92M |
Operating income | -114.35M | -22.07M | -43.21M | -17.19M | -9.92M |
Other income (expenses), net | 14.19M | 2.66M | 402K | 69K | 219K |
Income before tax | -100.16M | -19.41M | -42.81M | -17.12M | -9.70M |
Income tax expense | 0 | -4.01M | -674K | -69K | -219K |
Net income | -100.16M | -15.39M | -42.13M | -17.05M | -9.48M |
Earnings per share | |||||
Basic EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
Diluted EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Data source | Data source | Data source |